Lyra Therapeutics. has been granted a patent for innovative sinus scaffolds designed to treat chronic sinusitis. These scaffolds, which can include therapeutic agents like mometasone furoate, are delivered to specific sinus locations, enhancing localized treatment while avoiding placement in sinus ostia. GlobalData’s report on Lyra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lyra Therapeutics, was a key innovation area identified from patents. Lyra Therapeutics's grant share as of July 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Sinus scaffolds for treating chronic sinusitis
The granted patent US12064339B2 outlines a novel method for treating sinus conditions in human patients using a specialized scaffold. This scaffold consists of a first layer containing mometasone furoate, a corticosteroid, combined with a biodegradable polymer material, and a therapeutic-agent-free polymer topcoat layer. The scaffold is designed to be delivered to the middle meatus, facilitating the release of mometasone furoate from the middle meatus to the ethmoid sinuses, while ensuring that it is not placed in a sinus ostium. The method is particularly aimed at patients who have not responded to traditional medical management, including those who have failed treatment with oral or topical steroids.
Additionally, the patent describes methods for treating subjects who have undergone sinus surgery, specifically functional endoscopic sinus surgery. In these cases, the scaffold is delivered to the nasal passage to ensure effective delivery of mometasone furoate to the ethmoid sinuses. The claims also encompass scenarios where the scaffold delivery can be coordinated with a procedure known as sinuplasty, which may occur before, after, or simultaneously with the scaffold delivery. Overall, the patent presents a targeted approach to managing sinus conditions, particularly for patients with a history of inadequate response to conventional therapies.
To know more about GlobalData’s detailed insights on Lyra Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
